<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835730</url>
  </required_header>
  <id_info>
    <org_study_id>PE0139-PT-CL-0001</org_study_id>
    <nct_id>NCT01835730</nct_id>
  </id_info>
  <brief_title>Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhaseBio Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhaseBio Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human randomized, double-blind (Investigator and subject), placebo&#xD;
      controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo&#xD;
      per dose group) adult male and female subjects with Type 2 Diabetes Mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Vital Signs from baseline (Day 0 Pre-dose)</measure>
    <time_frame>Vital signs Day 0, 1, 2, 3, 4, 5, 6, 7, 14 and 28</time_frame>
    <description>Safety will be evaluated by analyses of the change from baseline in vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ECGs from baseline (Day -1)</measure>
    <time_frame>ECG Days 2 and 28</time_frame>
    <description>Safety will be evaluated by analyses of the change from baseline in 12-lead ECG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Safety Labs from baseline (Pre-dose)</measure>
    <time_frame>Safety Labs Days 0, 7 and 28</time_frame>
    <description>Safety will be evaluated by analyses of the safety laboratory parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of immunogenicity</measure>
    <time_frame>Immunogenicity Days 0, 7, 14 and 28</time_frame>
    <description>Safety will be evaluated by the incidence and severity of immunogenicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events including hypoglycemia</measure>
    <time_frame>As reported between Days -10 to 28</time_frame>
    <description>Safety will be evaluated by the incidence and severity of adverse events including hypoglycemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Day 0, 1, 2, 3, 4, 5, 6, and 7</time_frame>
    <description>Pharmacokinetic parameters include: Area under the concentration curve from time 0 to infinity (AUC(0-inf)), Area under the concentration curve to the final sample with a concentration greater than or equal to Limit of Quantitation (LOQ) (AUC(0-t)), Time to maximum concentration (Tmax), Maximum serum concentration (Cmax), Elimination rate constant (Lambda-z), Elimination half-life (t1/2), Clearance uncorrected for bioavailability (CL/F), Distribution uncorrected for bioavailability (Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Response</measure>
    <time_frame>FPG Day -10, -4, 0, 1, 2, 3, 4, 5, 6, 7, and 28; 4-pt Glucose and CGM - Day -10 to -7, -6, -5, and -4 to 7</time_frame>
    <description>To assess the pharmacodynamic response (time action profile) of various single doses of PE0139. Assessments include Fasting plasma glucose (FPG), 4-point serial glucose monitoring and glucose assessed by continuous glucose monitoring (CGM).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Type 2 Diabetes Mellitus (T2DM)</condition>
  <arm_group>
    <arm_group_label>PE0139 Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous injection of PE0139, 40 mg/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PE0139 Injection</intervention_name>
    <arm_group_label>PE0139 Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to sign a written informed consent and follow all study-related&#xD;
             procedures;&#xD;
&#xD;
          -  Male and female subjects at least 18 years of age;&#xD;
&#xD;
          -  Male subjects and female subjects of childbearing potential must practice effective&#xD;
             contraception during the study and be willing and able to continue contraception for&#xD;
             30 days after their dose of study drug;&#xD;
&#xD;
          -  Body mass index ≤45 kg/m2;&#xD;
&#xD;
          -  Diagnosed with T2DM and who is currently taking a stable daily dose of a basal insulin&#xD;
             (Lantus) plus at least one oral antihyperglycemic agent at a stable dose for 3 months&#xD;
             prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently taking or have taken within 3 months prior to screening an approved or&#xD;
             investigational GLP-1 analogue/agonist (e.g., Victoza®) or pramlintide;&#xD;
&#xD;
          -  Currently taking or have routinely taken, within 3 months prior to screening , a&#xD;
             short-acting insulin;&#xD;
&#xD;
          -  Currently taking or have taken, within 3 months prior to screening, a long acting&#xD;
             insulin other than Lantus®;&#xD;
&#xD;
          -  Known allergy to, or serious adverse effect caused by an approved, or investigational&#xD;
             insulin product or any of its components;&#xD;
&#xD;
          -  Currently taking any of the following medications: thiazide or furosemide diuretics,&#xD;
             beta-blockers, estrogens or other hormonal replacement therapy, or other chronic&#xD;
             medications with known adverse effects on glucose tolerance levels unless the subject&#xD;
             has been on stable doses of such agents for at least 2 months prior to screening and&#xD;
             have no planned changes during the study period;&#xD;
&#xD;
          -  History of recurrent severe hypoglycemia (more than 2 episodes within the last 6&#xD;
             months prior to randomization or hypoglycemic unawareness;&#xD;
&#xD;
          -  Malignant disease defined as 1) any history of malignant melanoma or breast cancer&#xD;
             and/or 2) history of other types of cancer within the last 5 years prior to screening;&#xD;
&#xD;
          -  Unstable cardiovascular disease defined as one or more of the following: History of&#xD;
             stroke, transient ischemic attack, or myocardial infarction within 6 months prior to&#xD;
             screening; History of or currently have New York Heart Association Class III-IV heart&#xD;
             failure prior to screening; Uncontrolled/sustained hypertension; History or evidence&#xD;
             of long QT syndrome or mean triplicate 12-lead electrocardiogram demonstrating QT&#xD;
             interval;&#xD;
&#xD;
          -  Clinically significant renal and/or hepatic dysfunction;&#xD;
&#xD;
          -  Absolute requirement for corticosteroids or have received systemic steroids within 3&#xD;
             months prior to Randomization (V5, Day -1). Note: Use of inhaled or topical&#xD;
             corticosteroids will be permitted;&#xD;
&#xD;
          -  Pregnant or lactating female subjects;&#xD;
&#xD;
          -  Known history of or active alcohol abuse or use of illicit drugs within 1 year prior&#xD;
             to screening;&#xD;
&#xD;
          -  Positive screening for human immunodeficiency virus antibodies, hepatitis B surface&#xD;
             antigen, or hepatitis C virus antibodies at V1;&#xD;
&#xD;
          -  Participating in any other study and have received any other investigational&#xD;
             medication or device within 30 days prior to Visit 1.&#xD;
&#xD;
          -  Other medical or psychiatric condition which, in the opinion of the Investigator,&#xD;
             would place the subject at increased risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Brazg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainier Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Springs Research Institute</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>October 13, 2014</last_update_submitted>
  <last_update_submitted_qc>October 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

